Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 14/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 6/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.39 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1976123 | 0.90 | MAP2K1 (0.54) | KCNH2CYP2C9MAP2K1MAP2K2PRKCZ | |
| SCHEMBL1980309 | 0.88 | MAP2K1 (0.55) | KCNH2CYP2C9MAP2K1MAP2K2PRKCZ | |
| SCHEMBL1977219 | 0.85 | MAP2K2 (0.41) | KCNH2CYP2C9MAP2K1MAP2K2 | |
| SCHEMBL1615474 | 0.85 | KCNH2 (0.68) | KCNH2CYP2C9MAP2K1MAP2K2IDO1 | |
| SCHEMBL1615911 | 0.83 | CYP2C9 (0.68) | KCNH2CYP2C9MAP2K1MAP2K2IDO1 | |
| SCHEMBL1977193 | 0.81 | KCNH2 (0.77) | KCNH2CYP2C9MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL12589903 | 0.81 | KCNH2 (0.56) | KCNH2CYP2C9MAP2K1MAP2K2PRKCZ | |
| SCHEMBL12589902 | 0.81 | KCNH2 (0.70) | KCNH2CYP2C9MAP2K1MAP2K2MAP2K5 | |
| Trifluoroacetic Acid SCHEMBL30185624 | 0.80 | KCNH2 (0.62) | KCNH2CYP2C9MAP2K1MAP2K2IDO1 | |
| SCHEMBL23694582 | 0.79 | CYP2C9 (0.56) | KCNH2CYP2C9MAP2K1MAP2K2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486963-B2 | Azaindolizines and methods of use | GENENTECH, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2220092-B1 | AZAINDOLIZINES AND METHODS OF USE | GENENTECH INC (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20110142826-A1 | AZAINDOLIZINES AND METHODS OF USE | GENENTECH, INC. | 2011-06-16 | — | — | US | disclosed |
| EP-2220092-A1 | AZAINDOLIZINES AND METHODS OF USE | Genentech, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009082687-A1 | AZAINDOLIZINES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142826-A1 | AZAINDOLIZINES AND METHODS OF USE | IKZF3, MKI67, CDKN1A | KCNH2 2385/4885CYP2C9 3114/4885MAP2K1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.